Department of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, Italy.
Accelera Srl, Milan, Italy.
Biofabrication. 2021 Apr 8;13(3). doi: 10.1088/1758-5090/abe4c4.
Cardiac toxicity still represents a common adverse outcome causing drug attrition and post-marketing withdrawal. The development of relevantmodels resembling the human heart recently opened the path towards a more accurate detection of drug-induced human cardiac toxicity early in the drug development process. Organs-on-chip have been proposed as promising tools to recapitulatethe key aspects of thecardiac physiology and to provide a means to directly analyze functional readouts. In this scenario, a new device capable of continuous monitoring of electrophysiological signals from functionalhuman hearts-on-chip is here presented. The development of cardiac microtissues was achieved through a recently published method to control the mechanical environment, while the introduction of a technology consisting in micro-electrode coaxial guides allowed to conduct direct and non-destructive electrophysiology studies. The generated human cardiac microtissues exhibited synchronous spontaneous beating, as demonstrated by multi-point and continuous acquisition of cardiac field potential, and expression of relevant genes encoding for cardiac ion-channels. A proof-of-concept pharmacological validation on three drugs proved the proposed model to potentially be a powerful tool to evaluate functional cardiac toxicity.
心脏毒性仍然是导致药物淘汰和上市后撤回的常见不良后果。最近,相关模型的发展类似于人类心脏,为在药物开发过程的早期更准确地检测药物引起的人类心脏毒性开辟了道路。器官芯片被提议作为一种有前途的工具,可以重现心脏生理学的关键方面,并提供直接分析功能读数的手段。在这种情况下,这里提出了一种新的设备,能够从功能型人心脏芯片上连续监测电生理信号。通过最近发表的一种控制机械环境的方法实现了心脏微组织的开发,而引入的一种由微电极同轴引导组成的技术允许进行直接和非破坏性的电生理学研究。生成的人心肌微组织表现出同步自发搏动,这一点通过多点和连续采集心电场电位以及编码心脏离子通道的相关基因的表达得到证明。对三种药物进行的概念验证药理学验证证明,所提出的模型有可能成为评估功能性心脏毒性的有力工具。